A multicentre Italian study evaluated 160 patients treated with dalbavancin and/or oritavancin in day hospital settings, with 54.4% receiving treatment for complex off-label infections. Overall clinical success was 86.8%, with comparable rates for ABSSSI and off-label indications (90.4% vs 83.7%; p=0.247). Adverse events were uncommon (3.3%), while a scenario-based economic analysis suggested the potential to reduce inpatient bed-days and associated costs. These findings support the feasibility of LAL-based day hospital pathways, although the absence of a comparator means that comparative efficacy and actual cost savings cannot be established.
Pharmacoeconomic data
Aug 2026
Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting
Marino A. et al – Pathogens,5, 740 - Published: 14 July 2026.
Costs of Oral Step-Down Antibiotic Treatment Versus Intravenous Hospital Antibiotic Treatment in Patients With Endocarditis: Cost Analysis From the POET Randomized Trial.
Kader N, et al. Circ Popul Health Outcomes. 2026 Aug 28:e014059.
A cost analysis of the 400-patient POET trial compared conventional intravenous therapy with oral step-down treatment in clinically stable patients with left-sided infective endocarditis. After randomization, oral step-down reduced median hospitalization from 19 to 3 days, corresponding to 16 fewer in-hospital bed days per patient. Despite additional outpatient visits, oral therapy was associated with €12,376 mean combined savings per patient, including lower hospitalization and antibiotic costs. Extrapolation to Denmark suggested potential annual savings of approximately €4.8 million, although cost estimates are healthcare-system dependent and did not include broader societal or post-discharge costs. The analysis supports oral step-down therapy as a strategy that, in appropriately selected and clinically stable patients, may reduce both hospital resource use and treatment-related costs.